Pacer Advisors’s Aimmune Therapeutics AIMT Stock Holding History

Pacer Advisors’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-5,531	Closed	-$191K	–	1554
2020 Q3	$191K	Buy	+5,531	New	+$118K	﹤0.01%	1185
2018 Q4	–	Sell	-3,532	Closed	-$96K	–	1148
2018 Q3	$96K	Buy	+3,532	New	+$99.9K	﹤0.01%	1097
2018 Q1	–	Sell	-500	Closed	-$19K	–	1164
2017 Q4	$19K	Buy	+500	New	+$16.1K	﹤0.01%	1101

Pacer Advisors's AIMT Position: Q4 2020 in Review

Pacer Advisors sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 5,531 shares — an estimated $191K sold.

Pacer Advisors first reported a position in AIMT in Q4 2017 and held it in 3 quarters. The position peaked at $191K in Q3 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

Pacer Advisors reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
Pacer Advisors sold 5,531 Aimmune Therapeutics shares in Q4 2020, an estimated $191K.
Pacer Advisors first reported a position in Aimmune Therapeutics in Q4 2017 and held it in 3 quarters.
Pacer Advisors's Aimmune Therapeutics position peaked at $191K in Q3 2020.
0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on Pacer Advisors's 13F filing for Q4 2020, filed 20 Jan 2021.